Skip to main content
Top
Published in: Virology Journal 1/2012

Open Access 01-12-2012 | Research

Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model

Authors: Jie Dai, En-Qiang Chen, Lang Bai, Dao-Yin Gong, Qiao-Ling Zhou, Xing Cheng, Fei-Jun Huang, Hong Tang

Published in: Virology Journal | Issue 1/2012

Login to get access

Abstract

Background

The effects of Hepatitis B virus (HBV) rtA181T/sW172* mutation on viral replication and pathogenicity was concerned recently. This study aimed to investigate the biological characteristics of rtA181T/sW172* mutant strain of HBV in animal model.

Methods

The rtA181T/sW172* mutant plasmid was constructed using the pHBV4.1 (wild type HBV) as a template. The wild and mutant HBV replication mouse models were established utilizing a hydrodynamic technique. The titers of hepatitis B surface antigen (HBsAg), hepatitis B e antigen, and HBV DNA in serum, and the levels of HBsAg, hepatitis B core antigen(HBcAg), HBV DNA replication intermediates (HBV DNA RI) and HBV RNA in liver were measured after 1, 3, 5, 7, 10, 12 and 15 days of plasmid injection.

Results

In wild-type HBV replication mouse model, serum HBsAg was high on day 1, 3, and 5, but became lower since day 7; while in mutant HBV mouse model, serum HBsAg was always at very low level. In liver tissues, HBV DNA RI of wild type HBV was detected on day 1 after transfection. The level subsequently peaked on day 3, gradually declined after day 5, and was almost undetectable on day 10. However, the HBV DNA RI levels of the mutant strain were always higher and lasted longer until day 15. Consistently, the expression levels of HBsAg and HBcAg in liver of the mutant group were significantly increased.

Conclusions

In the case of the HBV rtA181T/sW172* mutation, the secretion of serum HBsAg was impaired, whereas HBV DNA replication and HBsAg/HBcAg expression were increased in liver. These results suggest that the mutation can impair HBsAg secretion, and may cause the accumulation of viral core particles in liver.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bartholomeusz A, Locarnini S: Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006,78(Suppl 1):S52-S55.PubMedCrossRef Bartholomeusz A, Locarnini S: Hepatitis B virus mutations associated with antiviral therapy. J Med Virol 2006,78(Suppl 1):S52-S55.PubMedCrossRef
3.
go back to reference Michel ML, Tiollais P: Structure and expression of the hepatitis B virus genome. Hepatology 1987, 7: 61S-63S. 10.1002/hep.1840070711PubMedCrossRef Michel ML, Tiollais P: Structure and expression of the hepatitis B virus genome. Hepatology 1987, 7: 61S-63S. 10.1002/hep.1840070711PubMedCrossRef
4.
go back to reference Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48: 88-98. 10.1002/hep.22295PubMedCrossRef Warner N, Locarnini S: The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008, 48: 88-98. 10.1002/hep.22295PubMedCrossRef
5.
go back to reference Kim JH, Jung YK, Joo MK, Yim HJ, Park JJ, Kim JS, Bak YT, Yeon JE, Byun KS: Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci 2010, 25: 257-264. 10.3346/jkms.2010.25.2.257PubMedPubMedCentralCrossRef Kim JH, Jung YK, Joo MK, Yim HJ, Park JJ, Kim JS, Bak YT, Yeon JE, Byun KS: Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci 2010, 25: 257-264. 10.3346/jkms.2010.25.2.257PubMedPubMedCentralCrossRef
6.
go back to reference Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48: 747-755. 10.1016/j.jhep.2008.01.027PubMedCrossRef Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, Zoulim F: Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008, 48: 747-755. 10.1016/j.jhep.2008.01.027PubMedCrossRef
7.
go back to reference Lai MW, Yeh CT: The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13: 875-879.PubMed Lai MW, Yeh CT: The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008, 13: 875-879.PubMed
8.
go back to reference Liu FJ, Liu L, He F, Wang S, Zhou TY, Liu C, Deng LY, Tang H: Establishment and primary application of a mouse model with hepatitis B virus replication. World J Gastroenterol 2007, 13: 5324-5330.PubMedPubMedCentralCrossRef Liu FJ, Liu L, He F, Wang S, Zhou TY, Liu C, Deng LY, Tang H: Establishment and primary application of a mouse model with hepatitis B virus replication. World J Gastroenterol 2007, 13: 5324-5330.PubMedPubMedCentralCrossRef
9.
go back to reference Tang H, McLachlan A: Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA 2001, 98: 1841-1846. 10.1073/pnas.98.4.1841PubMedPubMedCentralCrossRef Tang H, McLachlan A: Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA 2001, 98: 1841-1846. 10.1073/pnas.98.4.1841PubMedPubMedCentralCrossRef
10.
go back to reference Tang H, McLachlan A: A pregenomic RNA sequence adjacent to DR1 and complementary to epsilon influences hepatitis B virus replication efficiency. Virology 2002, 303: 199-210. 10.1006/viro.2002.1645PubMedCrossRef Tang H, McLachlan A: A pregenomic RNA sequence adjacent to DR1 and complementary to epsilon influences hepatitis B virus replication efficiency. Virology 2002, 303: 199-210. 10.1006/viro.2002.1645PubMedCrossRef
11.
go back to reference Liu F, Song Y, Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6: 1258-1266. 10.1038/sj.gt.3300947PubMedCrossRef Liu F, Song Y, Liu D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999, 6: 1258-1266. 10.1038/sj.gt.3300947PubMedCrossRef
12.
go back to reference Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, Zhao L, Murakami S: The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005, 79: 5548-5556. 10.1128/JVI.79.9.5548-5556.2005PubMedPubMedCentralCrossRef Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, Zhao L, Murakami S: The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005, 79: 5548-5556. 10.1128/JVI.79.9.5548-5556.2005PubMedPubMedCentralCrossRef
13.
go back to reference Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H: Application of hepatitis B virus replication mouse model. World J Gastroenterol 2010, 16: 1979-1985. 10.3748/wjg.v16.i16.1979PubMedPubMedCentralCrossRef Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H: Application of hepatitis B virus replication mouse model. World J Gastroenterol 2010, 16: 1979-1985. 10.3748/wjg.v16.i16.1979PubMedPubMedCentralCrossRef
14.
go back to reference Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-1745. 10.1056/NEJM199712113372406PubMedCrossRef Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337: 1733-1745. 10.1056/NEJM199712113372406PubMedCrossRef
15.
go back to reference EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50: 227-242. 10.1016/j.jhep.2008.10.001CrossRef EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50: 227-242. 10.1016/j.jhep.2008.10.001CrossRef
16.
go back to reference Chien RN, Yeh CT, Wang PN, Kuo MC, Hsieh SY, Shih LY, Liaw YF: Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract 2004, 58: 1088-1091. 10.1111/j.1742-1241.2004.00266.xPubMedCrossRef Chien RN, Yeh CT, Wang PN, Kuo MC, Hsieh SY, Shih LY, Liaw YF: Acute leukaemia in chronic hepatitis B patients with lamivudine therapy. Int J Clin Pract 2004, 58: 1088-1091. 10.1111/j.1742-1241.2004.00266.xPubMedCrossRef
17.
go back to reference Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, et al.: Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006, 50: 3867-3874. 10.1128/AAC.00239-06PubMedPubMedCentralCrossRef Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, et al.: Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother 2006, 50: 3867-3874. 10.1128/AAC.00239-06PubMedPubMedCentralCrossRef
18.
go back to reference Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31: 1318-1326. 10.1053/jhep.2000.7296PubMedCrossRef Yeh CT, Chien RN, Chu CM, Liaw YF: Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000, 31: 1318-1326. 10.1053/jhep.2000.7296PubMedCrossRef
19.
go back to reference Schorr O, Borel C, Trepo C, Zoulim F, Hantz O: Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. J Hepatol 2006, 44: 842-847. 10.1016/j.jhep.2005.09.014PubMedCrossRef Schorr O, Borel C, Trepo C, Zoulim F, Hantz O: Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes. J Hepatol 2006, 44: 842-847. 10.1016/j.jhep.2005.09.014PubMedCrossRef
20.
go back to reference Schinazi RF, Ilan E, Black PL, Yao X, Dagan S: Cell-based and animal models for hepatitis B and C viruses. Antivir Chem Chemother 1999, 10: 99-114.PubMedCrossRef Schinazi RF, Ilan E, Black PL, Yao X, Dagan S: Cell-based and animal models for hepatitis B and C viruses. Antivir Chem Chemother 1999, 10: 99-114.PubMedCrossRef
21.
go back to reference Lentz TB, Loeb DD: Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011, 85: 11916-11927. 10.1128/JVI.05373-11PubMedPubMedCentralCrossRef Lentz TB, Loeb DD: Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011, 85: 11916-11927. 10.1128/JVI.05373-11PubMedPubMedCentralCrossRef
23.
go back to reference Weber B: Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 2006,78(Suppl 1):S59-S65.PubMedCrossRef Weber B: Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 2006,78(Suppl 1):S59-S65.PubMedCrossRef
24.
go back to reference Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336: 325-329. 10.1016/0140-6736(90)91874-APubMedCrossRef Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990, 336: 325-329. 10.1016/0140-6736(90)91874-APubMedCrossRef
25.
go back to reference Lou SC, Pearce SK, Lukaszewska TX, Taylor RE, Williams GT, Leary TP: An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011, 51: 59-63. 10.1016/j.jcv.2011.01.019PubMedCrossRef Lou SC, Pearce SK, Lukaszewska TX, Taylor RE, Williams GT, Leary TP: An improved Abbott ARCHITECT assay for the detection of hepatitis B virus surface antigen (HBsAg). J Clin Virol 2011, 51: 59-63. 10.1016/j.jcv.2011.01.019PubMedCrossRef
26.
go back to reference Chisari FV, Isogawa M, Wieland SF: Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58: 258-266. 10.1016/j.patbio.2009.11.001CrossRef Chisari FV, Isogawa M, Wieland SF: Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010, 58: 258-266. 10.1016/j.patbio.2009.11.001CrossRef
27.
go back to reference Chisari FV: Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156: 1117-1132. 10.1016/S0002-9440(10)64980-2PubMedPubMedCentralCrossRef Chisari FV: Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000, 156: 1117-1132. 10.1016/S0002-9440(10)64980-2PubMedPubMedCentralCrossRef
28.
go back to reference Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1: 23-61. 10.1146/annurev.pathol.1.110304.100230PubMedCrossRef Guidotti LG, Chisari FV: Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006, 1: 23-61. 10.1146/annurev.pathol.1.110304.100230PubMedCrossRef
29.
go back to reference Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, Brechot C: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22: 3911-3916. 10.1038/sj.onc.1206492PubMedCrossRef Paterlini-Brechot P, Saigo K, Murakami Y, Chami M, Gozuacik D, Mugnier C, Lagorce D, Brechot C: Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003, 22: 3911-3916. 10.1038/sj.onc.1206492PubMedCrossRef
30.
go back to reference Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, Paterlini-Brechot P: Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54: 1162-1168. 10.1136/gut.2004.054452PubMedPubMedCentralCrossRef Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C, Paterlini-Brechot P: Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut 2005, 54: 1162-1168. 10.1136/gut.2004.054452PubMedPubMedCentralCrossRef
31.
go back to reference Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, Kubo S, Shiomi S, Nishiguchi S: Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Canc Res 2005, 11: 5821-5826. 10.1158/1078-0432.CCR-04-2055CrossRef Tamori A, Yamanishi Y, Kawashima S, Kanehisa M, Enomoto M, Tanaka H, Kubo S, Shiomi S, Nishiguchi S: Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin Canc Res 2005, 11: 5821-5826. 10.1158/1078-0432.CCR-04-2055CrossRef
32.
go back to reference Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13: 29-60. 10.1146/annurev.iy.13.040195.000333PubMedCrossRef Chisari FV, Ferrari C: Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995, 13: 29-60. 10.1146/annurev.iy.13.040195.000333PubMedCrossRef
33.
go back to reference Locarnini S: Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2: 147-151. 10.1007/s12072-008-9048-3PubMedPubMedCentralCrossRef Locarnini S: Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008, 2: 147-151. 10.1007/s12072-008-9048-3PubMedPubMedCentralCrossRef
34.
go back to reference Julander JG, Sidwell RW, Morrey JD: Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 2002, 55: 27-40. 10.1016/S0166-3542(01)00223-6PubMedCrossRef Julander JG, Sidwell RW, Morrey JD: Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res 2002, 55: 27-40. 10.1016/S0166-3542(01)00223-6PubMedCrossRef
Metadata
Title
Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model
Authors
Jie Dai
En-Qiang Chen
Lang Bai
Dao-Yin Gong
Qiao-Ling Zhou
Xing Cheng
Fei-Jun Huang
Hong Tang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2012
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-9-280

Other articles of this Issue 1/2012

Virology Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.